文献速递核素与放射性配体治疗肿瘤 PET/CT

LUTADOSE试验:首次给药后的肿瘤剂量学预测接受[177Lu]Lu-DOTATATE治疗的胃肠胰神经内分泌肿瘤患者的无进展生存期

The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-09-05

该前瞻性观察性研究纳入42例G1-G2级胃肠胰神经内分泌肿瘤患者(165个病灶),在4次[177Lu]Lu-DOTATATE标准方案给药后,于第1次和第4次给药后行双次SPECT/CT剂量学检测。中位随访32.8个月,中位无进展生存期(PFS)为42个月,第20个月PFS率为90.5%。首次给药后全局肿瘤吸收剂量(GTD_1)与PFS>24个月或<24个月显著相关,以10.6 Gy为最佳截断值时,低于该值组中位PFS为21个月,高于该值组未达到(长于45.5个月)(p=0.004,风险比8.6,95%CI 2-37)。

要点

  • 首次给药后GTD_1与PFS>24个月或<24个月显著相关(p=0.026),GTD_TOT同样相关(p=0.03)。
  • GTD_1以10.6 Gy为截断值分层,中位PFS为21个月 vs 未达到(长于45.5个月),p=0.004,风险比8.6(95%CI 2-37)。
  • GTD_TOT以43 Gy为截断值分层,获得与第1周期后相同的PFS值(p=0.035)。

核心结论

  • 首次给药后[177Lu]Lu-DOTATATE肿瘤剂量学在临床决策过程中具有重要预后价值,尤其在未来替代发射体或给药方案可能出现时。
  • 多项统计分析似乎证实,首次给药后仅行2次SPECT/CT的简单肿瘤剂量学可预测4次×7.4 GBq [177Lu]Lu-DOTATATE给药后的PFS值(G1-G2级胃肠胰神经内分泌肿瘤)。

研究设计与样本

  • 前瞻性观察性研究,纳入42例接受4次给药的G1-G2级胃肠胰神经内分泌肿瘤患者,分析165个病灶。
  • 在第1次和第4次给药后行剂量学检测,每次给药后第1天和第7天各行1次SPECT/CT扫描(共2次)。
  • 患者通过血液检查和增强CT随访,中位随访32.8个月(范围18-45.5个月)。

主要发现

  • 中位随访33个月(范围18-45.5个月),中位PFS为42个月,第20个月PFS率为90.5%。
  • GTD_1和GTD_TOT均与PFS>24个月或<24个月显著相关(分别为p=0.026和p=0.03)。
  • GTD_1低于或高于最佳截断值10.6 Gy分层后,中位PFS分别为21个月 vs 未达到(长于45.5个月),p=0.004,风险比8.6(95%CI 2-37)。
  • GTD_TOT以最佳截断值43 Gy分层后,获得与第1周期后相同的PFS值(p=0.035)。
  • 多因素分析中,GTD_1降低与PFS<24个月显著相关,全局肿瘤体积较高影响较小但亦显著相关。

关键数值与推荐

  • GTD_1最佳截断值为10.6 Gy,低于该值组中位PFS为21个月,高于该值组未达到(长于45.5个月),p=0.004,风险比8.6(95%CI 2-37)。
  • GTD_TOT最佳截断值为43 Gy,分层后PFS值与第1周期后相同(p=0.035)。
  • GTD_1和GTD_TOT与PFS>24个月或<24个月的关联分别为p=0.026和p=0.03。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,首次给药后[177Lu]Lu-DOTATATE肿瘤剂量学在临床决策过程中具有重要预后价值,尤其在未来替代发射体或给药方案可能出现时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTATATE of gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) a question remains open about the potential benefits of personalised dosimetry. This observational prospective study examines the association of individualized dosimetry with progression free survival (PFS) in G1-G2 GEP NETs patients following the standard [177Lu]Lu-DOTATATE therapeutic regimen. METHODS: The analysis was conducted on 42 patients administered 4 times, and on 165 lesions. Dosimetry was performed after the first and the forth cycle, with two SPECT/CT scans at day 1 and 7 after administration. Global mean Tumour absorbed Dose of each patient (GTD) was calculated after cycle 1 and 4 as the sum of lesion doses weighted by lesion mass, normalized by the global tumour mass. Cumulative GTD_TOT was calculated as the mean between cycle 1 (GTD_1) and 4 (GTD_4) multiplied by 4. Patients were followed-up for median 32.8 (range 18-45.5) months, through blood tests and contrast enhanced CT (ceCT). This study assessed the correlation between global tumour dose (GTD) and PFS longer or shorter than 24 months. After a ROC analysis, we stratified patients according to the best cut-off value for two additional statistical analyses. At last a multivariate analysis was carried out for PFS > / < 24 months. RESULTS: The median follow-up interval was 33 months, ranging from 18 to 45.5 months. The median PFS was 42 months. The progression free survival rate at 20 months was 90.5%. GTD_1 and GTD_TOT were statistically associated with PFS > / < 24 m (p = 0.026 and p = 0.03 respectively). The stratification of patients on GTD_1 lower or higher than the best cut-off value at 10.6 Gy provided significantly different median PFS of 21 months versus non reached, i.e. longer than 45.5 months (p = 0.004), with a hazard ratio of 8.6, (95% C.I.: [2 - 37]). Using GTD_TOT with the best cut-off at 43 Gy, the same PFS values were obtained as after cycle 1 (p = 0.035). At multivariate analysis, a decrease in GTD_1 and, with lower impact, a higher global tumour volume were significantly associated with PFS < 24 months. We calculated the Tumour Control Probability of obtaining PFS > 24 months as a function of GTD_1. DISCUSSION: Several statistical analyses seem to confirm that simple tumour dosimetry with 2 SPECT/CT scans after the first administration allows to predict PFS values after 4 × 7.4 GBq administrations of 177Lu[Lu]-DOTATATE in G1-G2 GEP NETs. This result qualitatively confirms recent findings by a Belgian and a French study. However, dosimetric thresholds are different. This probably comes from different cohort baseline characteristics, since the median PFS in our study (42 m) was longer than in the other studies (28 m and 31 m). CONCLUSION: Tumour dosimetry after the first administration of [177Lu]Lu-DOTATATE offers an important prognostic value in the clinical decision-making process, especially for the future as alternative emitters or administration schedule may become available.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Maccauro M, Cuomo M, Bauckneht M, et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024. PMID: 39235614. doi:10.1007/s00259-024-06863-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。